HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearchCompany Lookup
The Week

'We're moving quickly': Startup bags rare disease drug as Thiel-backed CEO eyes $50M fundraise

A rare disease startup with a mission to repurpose proven drugs has licensed a Chinese formulation of a well-known medicine and set its sights on a $50 million fundraise.

By FierceBiotech · Jul 22, 2026 · via FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Amgen agrees to $74M settlement to resolve investor lawsuit over potential $10.7B tax bill
Amgen has agreed to a $74 million settlement with investors to resolve a lawsuit that alleged the company hid …
Jul 22, 2026
Novo Nordisk’s GLP‑1 suit and Anthropic’s biotech push headline the week
The WeekBriefing
Novo Nordisk’s GLP‑1 suit and Anthropic’s biotech push headline the week
Novo Nordisk filed suit against Eli Lilly over GLP‑1 drugs as Anthropic deepened its rare‑disease biotech work…
Jul 22, 2026
STAT+: 'Cochlear implant for blindness' debuts in Europe, could launch in U.S. in 2027
The WeekSTAT News ↗
STAT+: 'Cochlear implant for blindness' debuts in Europe, could launch in U.S. in 2027
Science Corporation announced the European launch of its retinal implant for patients with age-related macular…
Jul 22, 2026